ciltacabtagene autoleucel + 64Cu superparamagnetic iron oxide nanoparticle

Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The therapy involves collecting a patient’s own T cells, genetically modifying them to express a CAR targeting BCMA, and infusing them back into the patient to target and eliminate BCMA-expressing myeloma cells[5][7]. The combination "cilta-cel + 64Cu SPION" refers to labeling cilta-cel with copper-64-labeled superparamagnetic iron oxide nanoparticles (SPIONs), enabling dual PET/CT and MRI imaging for in vivo tracking of cell trafficking after infusion. This approach is being investigated in clinical trials for its ability to visualize the biodistribution of infused CAR-T cells in patients with advanced or extramedullary multiple myeloma[1][2][3]. Preclinical studies show that Cu-64 SPION labeling does not impair cilta-cel viability or function[2][3].

Brand names

CARVYKTI

Other names

cilta-cel + 64Cu SPIONciltacabtagene autoleucel + copper-64 superparamagnetic iron oxide nanoparticle